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Introduction
Ordinal outcomes, or any outcome with inherent ordering, 
occur frequently in biomedical data. Examples of these types 
of ordered responses include severity of depression, grading of 
adverse events, the Knodell score for liver biopsies,1 or stage 
of cancer. Stage of cancer is a pathological description of a 
tumor, and for breast cancer it considers the following: size 
of the tumor, number of cells in the tumor, location of tumor 
with respect to the chest wall and skin, the amount of cancer 
in mammary, axillary, and sentinal lymph nodes, the number 
of lymph nodes involved, and the spread of cancer to other 
organs.2 Stage of cancer typically determines the course of 
therapy and is most often ascertained through a biopsy of the 
cancerous tissue. When modeling stage of cancer, it may be of 
interest to predict which response level a patient may exhibit, 
given some set of explanatory variables. Ordinal regression 
may be used to model the probability of exhibiting a spe-
cific ordinal response, given some set of relevant covariates. 
However, ordinal regression methods require either that the 
sample size exceeds the number of features or that all covari-
ate parameters be penalized. It is of interest here to develop 
a method that allows the model to penalize some covariates 
without penalizing others (such as demographic covariates).
In our research, we are interested in using high- 
dimensional methylation data from the Illumina Human 
Methylation 450K technology, in conjunction with other fac-
tors, to predict stage of cancer in a sample of women with 
breast cancer. Methylation is an epigenetic event that alters 
gene expression without altering the DNA sequence itself. 
It is the process by which a cytosine molecule on the DNA 
strand becomes a 5-methylcytosine through the addition of 
a methyl group, or a 5-hydroxymethylcytosine through the 
addition of a methyl group followed by a hydroxy group. Pro-
found methylation changes are known to occur in the context 
of cancer; well-documented changes include the hyperm-
ethylation of tumor-suppressor genes3 and the hypomethy-
lation of proto-oncogenes.4 Specific patterns of methylation 
exhibited in tumors are thought to not only detect cancer5 but 
also predict tumor behavior6 and illuminate differences and 
similarities across and within tumor types.3 Jones and Laird 
stated that perhaps methylation patterns in cells could serve as 
“a rough blueprint for the expression profile of that cell” and 
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envisioned that future development of science and technology 
might produce a useful methylation analysis to generate a 
“DNA methylation fingerprint for a tumor biopsy.”7 Studies 
of methylation patterns in peripheral blood specimens from 
people diagnosed with cancer have also shown alterations. Of 
particular relevance, DNA methylation analysis from periph-
eral blood samples recently identified an association between 
methylation of the HYAL2 gene and breast cancer,8 suggest-
ing that methylation patterns in blood might be useful as a 
screening tool for evaluating tumors in other tissues. Because 
epigenetic changes, such as methylation, are reversible, iden-
tification of specific methylation changes occurring in specific 
cancers may lead to targeted therapies to return normal func-
tion to the cells.7 Given this evidence, we hypothesized that 
differential methylation may be predictive of stage of cancer in 
women with breast cancer.
Methods
data. In this paper, we worked with one dataset from 
a breast cancer study conducted at Virginia Commonwealth 
University. This research was approved by the Institutional 
Review Board at Virginia Commonwealth University (VCU 
IRB #HM 13194) and complied with the principles of the 
Declaration of Helsinki. Our dataset included 73 women with 
breast cancer and included baseline clinical and demographic 
covariates such as estrogen receptor (ER), progesterone receptor 
(PR), and human epidermal growth factor receptor 2 (HER2) 
status, age, race (white or African-American), prior breast can-
cer surgery (lumpectomy, segmental, or simple surgery prior 
to study enrollment), and smoking status (currently smoking, 
yes or no). ER, PR, and HER2 status were collapsed into a 
single, categorical measure of breast cancer subtype,9 defined 
in Table 1.
Peripheral blood samples were collected at study entry, 
and DNA was subsequently extracted from these samples 
using standard methods, bisulphite converted (Zymo Research 
EZ Methylation Kit), and hybridized to Illumina’s Human 
Methylation 450K array according to the manufacturer’s pro-
tocol. To assess assay reliability, some samples were hybridized 
multiple times, resulting in a total of 82 methylation profiles.
The scanned arrays were processed using the minfi10 Bio-
conductor package in the R programming environment to 
obtain the β-values for each probe, where βig represents the 
proportion methylated for the ith sample and the gth CpG 
site, defined here as
   β = + +
M
M U offset
where M is the methylated signal for a given CpG site, U  is 
the unmethylated signal for a given CpG site, and offset is 
100, to avoid division by small numbers.11
Some preprocessing of the methylation data was neces-
sary prior to statistical analysis. Our first preprocessing step 
was to look at the distribution of β-values by the GC content. 
This is important because previous research has established 
that methylation may not be accurately measured in regions 
of high GC content.12 Illumina’s design for the 450K array 
includes two separate assays, Type I and Type II, for estimat-
ing methylation at a given locus. GC content was calculated as 
the proportion of the probe sequence comprised of C’s and G’s 
and reported separately for Type I and Type II design types. 
We then examined the boxplots of average β-values (across 
all samples) by the GC content for each of the assay types 
separately (Figs. 1 and 2). The resulting boxplots were used to 
determine a GC proportion cutoff value beyond which methy-
lation seems to no longer be reliably measured. The choice of 
such a cutoff is clearly subjective, but it is important to remove 
the CpG sites beyond the cutoff because inclusion of unreli-
able probes may distort the analysis. We also removed CpG 
sites within which there were known single nucleotide poly-
morphisms (SNPs) according to the Illumina-provided anno-
tation files.11
The Type I design includes two bead types for each CpG 
site: one that detects methylated CpG sites, and the other 
Table 1. Criteria for breast cancer subtype classification.
SUBTYPE DEfINITION
Luminal a er+ and/or Pr+, Her2−
Luminal B er+ and/or Pr+, Her2+
triple negative er−, Pr−, Her2−
Her2 type er−, Pr−, Her2+
Notes: Breast cancer subtype classification typically considers proportion of 
tumor cells positive for the Ki67 protein. this measurement was not collected 
in our study and therefore could not be used for classification.
GC Content, Type I
Percentage
β
1.0
0.8
0.6
0.4
0.2
0.0
18 24 30 36 42 48 54 60 66
figure 1. Boxplot of mean β-values by percent GC content across all 
samples, for type I probes.
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that detects unmethylated CpG sites. The Type II design 
includes a single bead with a two-color readout; a different 
color is used to indicate whether the CpG site is methylated 
or unmethylated. In 2011, Dedeurwaerder et al examined 
the distribution of β-values produced by Type I and Type II 
bead types used in the 450K technology.13 They noted that 
the distribution of β-values from both bead types, across the 
whole array, exhibited two distinct peaks, one close to 0 for 
the unmethylated CpGs and one close to 1 for the methy-
lated CpGs. These peaks, however, when modeled separately 
by bead type, did not align exactly; the peaks for the β-values 
from the Type II beads were shifted inwards when compared 
to the Type I beads. This shift is attributed to the difference 
in chemistry between the beads and is acknowledged by Illu-
mina in a Technical Note for the 450K technology on their 
Web site.14 To correct this issue, we implemented the peak 
correction method by Dedeurwaurder et al on our β-values as 
a preprocessing step. This method adjusts the Type II peaks 
so that they align to the locations of the Type I peaks. The 
peak correction method uses the M-values and the logit of the 
β-values
   
Mig
ig
ig
=
−( )








log .
β
β1
Prior to the logit transformation and peak correction, we 
modified the β-values slightly by adding or subtracting 0.001 
to any β-value exactly equal to 0 or 1, respectively, in order to 
prevent errors during the logit transformation.
Finally, there were five patients having n1 = 4, n2 = 4, 
n3 = 2, n4 = 2, and n5 = 2 hybridized samples each. For 
each of these patients, we averaged the final peak-corrected 
M-values across the replicate samples and used this single, 
mean signal for each of these five patients in our analysis. 
All data analyses were conducted in R (version 3.1.0) uti-
lizing the minfi10 (version 1.10.2), limma15 (version 3.16.8), 
VGAM (version 0.9–4),16 and ordinalgmifs17 (version 1.0.2) 
packages. In our analysis, we used the 450K annotation file 
version 1.2.18
Analysis. In genomic research, traditional modeling 
methods are often inappropriate. Traditional ordinal regres-
sion methods, for example, require that the number of pre-
dictors (p) be smaller than the sample size (n) and that the 
predictors be independent. After filtering, our breast can-
cer study included 353,331 CpG sites and only 73 patients; 
such a situation, where p .. n, is typical when analyzing 
high-throughput genomic data. Furthermore, we know that 
methylation levels of CpG sites in close proximity to one 
another are highly correlated. To handle these challenges, 
we implemented penalized regression methods. Penalized 
regression introduces bias into the model in exchange for 
reducing variability.19 The resulting model is sparse, which is 
an attractive feature when dealing with an overly large pre-
dictor space and we are interested in producing a parsimoni-
ous model.
There are a variety of algorithms available for finding a 
penalized solution. One such algorithm is the Incremental For-
ward Stagewise (IFS) method, which provides the monotone 
Least Absolute Shrinkage and Selection Operator (LASSO) 
solution in a linear regression setting.20 Hastie et al modified 
and extended the IFS procedure, creating the generalized 
monotone incremental forward stagewise (GMIFS) method, 
which provides a penalized solution in a logistic regression 
setting.20 Archer et al further extended the GMIFS method 
to provide the penalized solution in an ordinal regression set-
ting.21 In our work, we extended the GMIFS algorithm to 
allow a subset of covariates to be included in the model with-
out penalization.
This so-called no-penalty subset, the subset of demo-
graphic variables not penalized, is included in the final model, 
and the fitting algorithm is not allowed to shrink any of these 
coefficients to 0. This no-penalty subset option is important 
in many scientific investigations where some biologically 
relevant demographic information should be retained in the 
model, regardless of statistical significance ascribed to the 
given covariates. For our breast cancer dataset, we fit univari-
ate ordinal response models predicting stage for each of the 
following: age, race, body mass index (BMI), smoking status, 
prior surgery related to the management of breast cancer, and 
subtype, to see which of these will be important for inclu-
sion in the full ordinal model. We conducted a likelihood ratio 
test (LRT) to obtain the P-values for each of these univariate 
models. We used a P-value cutoff of 0.05 to determine which 
demographic covariates were important for inclusion in the 
no-penalty subset.
GC Content, Type II
β
Percentage
1.0
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0.6
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figure 2. Boxplot of mean β-values by percent GC content across all 
samples, for type II probes.
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Given the large number of CpG sites in the 450K 
array, we first filtered the M-values by significance in order 
to reduce the number of penalized coefficients considered by 
the model. We fit a model with only the demographic covari-
ates found to be important from the previous LRTs and each 
of the CpG sites individually. We then conducted a series of 
LRTs between the demographic-only model and each of the 
CpG site models. Using a liberal P-value threshold of 0.25, 
we included in the penalized model only those CpG sites with 
a P-value ,0.25. Additionally, we removed CpG sites that 
were universally unmethylated (β , 0.1) across all samples 
and those that were universally methylated (β . 0.9) in all 
samples. Removing these CpG sites constituted no loss of 
information since all the samples were either fully unmethy-
lated or fully methylated.
The primary outcome measure of interest, as mentioned, 
was stage of cancer. Stage of cancer is measured as 0–IV and 
may be further subdivided into 0, IA-B; IIA-B; IIIA–C; and 
IV. The patients in our study, which focused on ascertaining 
participants with early stage breast cancer, were classified as 
stage I (n = 21), IIA (n = 29), IIB (n = 15), or IIIA (n = 8). We 
constructed a response matrix y which was an n × k matrix 
representing class membership. For i = 1,…, n, subjects may 
take one of j = 1,…, k stages (ordinal levels), and the elements 
of the matrix are
   
y
i j
ij =




1
0
,
,
if observation is in stage
otherwise.
We also constructed a matrix of nonpenalized predictors z 
and a matrix of penalized predictors x. Using a cumulative 
logit model to model the k – 1 logits of ordinal categories 
at or below a given level, the probability of interest may be 
expressed as follows:
   
where αj ’s represent the intercepts and β, and θ represent the 
coefficients for the penalized and nonpenalized predictors, 
respectively. In this way, we modeled the conditional prob-
ability that, given values of the demographic and methylation 
covariates, the cancer classification for a patient would fall at 
or below a certain stage. The conditional probability that the 
cancer classification would fall exactly at a certain stage may 
be written as
 
( )
( )
Therefore, the likelihood is given by
   
and the log-likelihood is given by
   
which can be more formally expressed as
The specific steps of the modified GMIFS algorithm 
to obtain this solution are implemented in the ordinalgmifs 
package in R.17 We outline the steps for the cumulative logit 
form of the model here.
1. Beginning at step s = 0,
Augment the x covariate space by appending the negative 
of the covariate space so that x becomes [x: –x].*
*We augment the covariate space in this way so that we may 
avoid calculation of the second derivative to determine the direction 
of the update.20
2. Set all of the β terms to 0 so that 
(The β vector is of length 2p)
3. Initialize the α terms as α j in kj
y
n
ij= ( )= =∑ ∑logit 1 1 .
4. Holding the β terms fixed, update α and θ by maximum 
likelihood.
5. Holding α and θ fixed, find m
p p
= − ( )argmin logδδβ L .
6. Update βms+1  to be β εms+ +1 ,  where ε  is some small value. 
We used ε = 0.01.
7. Repeat steps 4–6 until log L(s+1) − log L(s) , τ, where τ is 
some small value. We used τ = 0.00001.
Once the algorithm converges, the parameter estimates 
achieved constitute the “converged model.” For each step of 
the algorithm, we calculated the log likelihood, Akaike Infor-
mation Criterion (AIC), and the Bayesian Information Cri-
terion (BIC) for the model at that iteration of the algorithm. 
AIC and BIC are measures of the relative quality of a statisti-
cal model. We then extracted the parameter estimates at the 
step that minimized the AIC. 
The penalized covariates are given by x, with β denot-
ing the corresponding parameter estimates. As indicated in 
step 2 of the algorithm, at the first step all the β ’s are set to 
zero. For each consecutive step of the algorithm, only one β 
Penalized ordinal method for predicting stage of cancer
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is updated by a very small incremental amount. As indicated 
in steps 5 and 6 of the algorithm, the β that is updated is that 
which corresponds to the predictor having the largest negative 
derivative of the log likelihood. After a β has been updated, 
the thresholds and unpenalized predictors are estimated by 
maximum likelihood keeping the β fixed (see step 4 of the 
algorithm). For this reason, some predictors are penalized (x) 
while others are not penalized (z). The penalized β estimates 
are found when the log likelihood is minimized with respect 
to the following constraints:
 
β β β βg g g g
g
G
s+ − + −
=
≥ +( ) ≤∑, 0
1
and
The value of s is not specified by the user. Rather, each of the 
s values corresponds to a specific solution20 so that both the 
AIC-selected and the converged model will have an associ-
ated s value. Note that this method is an incremental forward 
stagewise method, which differs from preselecting a tuning 
parameter, or set of tuning parameters, against which the 
model is fit, then subsequently selecting the best fitting model 
by some model-fitting criterion.
For our selected model, we were interested in how the 
blood methylation values predicted the stage of the actual 
tumor. For the nonzero coefficient estimates, we investigated 
whether any of the differentially methylated loci had been pre-
viously associated with breast cancer or other types of cancer.
simulation study. We also conducted a simulation study 
to further test the performance of the method. Currently, there 
exists no comparative method that fits a penalized cumulative 
logit model, so we have no method against which to test the 
GMIFS cumulative logit model performance. For our simula-
tion study, we used a sample size of 80 subjects, where 100 
predictor variables were generated from a uniform distribution 
on the [–1, 1] interval. Thereafter, the latent response, yi*  for 
i = 1,…, 80, was generated by using the first four predictors 
(X1,…, X4) as covariates truly associated with the response 
where the coefficients were (0.5, –0.5, 0.5, –0.5) and adding 
a Gaussian error term with mean 0 and standard deviation of 
0.15. The observed response was generated by referencing the 
probabilities of the generated latent response using a standard 
normal distribution, where the observed class was taken to be
   
y
P y
P y
P yi
i
i
i
=
( ) ≤
< ( ) ≤
< ( ) ≤
1 0 25
2 0 25 0 50
3 0 50 0 75
4
if
if
if
if
*
*
*
.
. .
. .
P yi* .
.
( ) >






 0 75
 (1)
Thereafter, a cumulative logit GMIFS model was fit using 
X1 as an unpenalized predictor and X2, X3, X4 as penalized 
predictors and the AIC selected model was examined. This 
entire process was repeated 50 times. Characteristics of the 
fitted models examined included the number of times the 
coefficients for X2, X3, and X4 were nonzero (true positive 
rate); the number of times the coefficients for X5,…, X100 were 
nonzero (false positive rate); and the misclassification rate.
Our simulation study indicated that the method per-
formed well. The true positive rate was 100%, as all models 
returned nonzero coefficient estimates for X2, X3, and X4. The 
median false positive rate was 5.2% (range 0–33%). The median 
misclassification rate was 13.75% (range 1.25–30.00%).
results
Table 2 provides an overview of the distribution of the con-
tinuous and binary demographic covariates by stage of cancer. 
Table 3 provides the distribution of the multi-level categorical 
covariate.
The original, unfiltered data had 485,512 CpG sites. 
The boxplots of GC content by CpG site (Figs. 1 and 2) 
indicate that methylation may not be accurately measured 
beyond 42% for Type I probes or beyond 40% for Type II 
probes. After examining these boxplots, we chose the more 
conservative of the two values and excluded CpG sites with 
greater than 40% GC content from further analysis. This GC 
content filtering criteria removed 52,077 CpG sites, leaving 
433,435 CpG sites. Next we removed the 80,104 CpG sites 
that included SNPs, leaving 353,331 CpG sites. There were 
1,742 β-values exactly equal to 0, while none were exactly 
equal to 1. We imputed those equal to 0 to be 0.001 before 
applying the logit transform. After this, we applied the peak 
correction method to align the Type II peaks to the locations 
of the Type I peaks. An LRT was conducted for each of the 
demographic covariates comparing the intercepts-only model 
to each of the univariate models when fitting cumulative logit 
models to predict stage of cancer. The results of these tests are 
given in Table 4.
Table 2. Demographic characteristics by stage of cancer. the 
medians are reported for continuous variables (age and BmI) and 
the frequencies are reported for categorical variables (race, smoking 
status, and prior surgery).
STAgE I
n = 21
IIA
n = 29
IIB
n = 15
IIIA
n = 8
TOTAL
n = 73
age (median)
BmI (median)
55
29.58
48
25.79
56
31.01
49
29.25
53
28.34
race (Black)
Currently smoking (Y)
Prior surgery (Y)
5/21
3/21
21/21
10/29
5/29
26/29
6/15
6/15
12/15
0/8
1/8
7/8
21/73
15/73
66/73
Table 3. frequencies of breast cancer subtype by stage of cancer.
STAgE I
n = 21
IIA
n = 29
IIB
n = 15
IIIA
n = 8
TOTAL
n = 73
Luminal a 7 16 7 7 37
Luminal B 2 3 3 0 8
triple negative 11 7 2 1 21
Her2 type 1 3 3 0 7
Gentry et al
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Table 4. Lrt and resulting P-values from univariate cumulative logit models predicting stage of cancer.
INTERCEPTS ONLY AgE BMI RACE CURRENTLY SMOkINg PRIOR SURgERY SUBTYPE
Deviance 
χ12 statistic
188.72 187.57
1.15
188.70
0.02
188.69
0.03
187.56
1.16
185.70
3.02
179.91
8.81*
P-Value 0.2834 0.8787 0.8611 0.2821 0.0824 0.0319
Note: *χ 32 statistic.
Table 5. aIC-selected CpG sites listed with their chromosome, position, and associated UCsC ref genes, where appropriate.
CPg SITE CHROMOSOME LOCATION (START) LOCATION (END) UCSC REf gENE
cg01393985 6 89927651 89927700 GABRR1
cg02873991 12 25151263 25151312 C12orf77
cg02990147 X 24329623 24329672 FAM48B2
cg03478356 9 45726913 45726962 FAM27A
cg03604519 X 70150242 70150291 SLC7A3
cg03642328 11 69624925 69624974 FGF3
cg04315214 1 2043799 2043848 PRKCZ
cg05898699 18 15197299 15197348
cg06159404 10 43846376 43846425
cg06618740 1 1100126 1100175
cg07068358 16 25879737 25879786 HS3ST4
cg07078747 12 34177660 34177709 ALG10
cg07850592 1 231299396 231299445 TRIM67
cg08314875 Y 15015601 15015650 DDX3Y
cg08407901 21 43989901 43989950 SLC37A1
cg08615372 19 18699234 18699283 C19orf60
cg08833952 22 22469409 22469458
cg09667394 1 78011748 78011797 AK5
cg10139947 2 105274650 105274699
cg10467557 13 21893614 21893663
cg12386614 1 33608005 33608054
cg12440927 7 157791673 157791722 PTPRN2
cg13033971 13 46291925 46291974
cg14468658 5 140723461 140723510 PCDHGA2, PCDHGA3, PCDHGA1
cg14884760 22 50164389 50164438
cg16807687 10 85973970 85974019 PCDH21
cg19009644 3 10553211 10553260
cg19149522 7 6616375 6616424 ZDHHC4
cg19893664 14 105619634 105619683 JAG2
cg20418394 10 72254335 72254384 KIAA1274
cg21156276 9 4491869 4491918 SLC1A1
cg24493834 6 129250963 129251012 LAMA2
cg25099892 13 113313857 113313906 C13orf35
cg26479305 12 52470979 52471028 C12orf44
cg27161197 12 47224649 47224698
In the interest of developing a parsimonious model, 
we used a P-value cutoff of 0.05. At this significance level, 
it was clear that only subtype (eg, Luminal A; Luminal B; 
HER2+; triple negative) was significantly related to stage 
of breast cancer in this univariate sense. A similar LRT was 
conducted for each of the 353,331 CpG sites using the filtered, 
peak-corrected β-values. The model for the LRTs included 
only the demographic variable for cancer subtype. After 
Penalized ordinal method for predicting stage of cancer
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excluding CpG sites with P-values greater than 0.25, 103,001 
CpG sites remained. Finally, after excluding CpG sites for 
which the β-value was ,0.1 or .0.9 in all samples, 27,110 
CpG sites remained. The ordinal cumulative logit GMIFS 
model was fit to the subtype covariate as a nonpenalized pre-
dictor and to the M-values for the 27,110 CpG sites as penal-
ized predictors. The model attaining minimum AIC included 
35 nonzero CpG sites (Table 5), while the fully converged 
model estimated 107 nonzero CpG sites. Subsequently, we 
ran the model again, this time filtering to exclude CpG sites 
with P-values greater than 0.05. Fitting the same GMIFS 
model to this smaller set of CpG sites resulted in exactly the 
same parameter estimates and class predictions as the previous 
model, which used a P-value cutoff of 0.25.
Boxplots (Figs. 3 and 4) are shown for the two CpG sites 
from Table 5 with the largest absolute coefficient. The plots 
display the distribution of β-values for all subjects according 
to stage of cancer. The β-values for cg19149522 (ZDHHC4) 
seem to be monotonically decreasing, while the β-values for 
cg16807687 (PCDH21) seem to be monotonically increasing.
The fully converged model predicted the stage without 
error, while the minimum AIC model had an error rate of 
15.1%. Table 6 shows the cross-tabulation of observed versus 
predicted class. The fully converged model was without error; 
however, it included 107 nonzero parameter estimates indicat-
ing that it is likely overfit. The AIC model was less accurate 
for prediction, particularly for patients with stage IIIA cancer. 
This is likely due to the fact that our patient sample is unbal-
anced across the stages and is biased toward stages I–IIB.
discussion
In this paper, we presented an ordinal response model for 
high-dimensional covariate spaces that allows the inclusion 
of nonpenalized covariates, penalized covariates, or both. 
This method can be applied to any cumulative link, forward 
continuation ratio, backward continuation ratio, adjacent 
category, or stereotype logit model using the ordinalgmifs R 
package.17 While the fully converged model had 100% accu-
racy in predicting stage of cancer, there were several misclas-
sifications for the AIC-selected model. This may be partially 
attributed to the imbalance and small class size, particularly 
for stage IIIA. However, several of the CpG sites included 
in the models were located within genes that have previously 
been associated with breast cancer. AK5, PTPRN2, LAMA2, 
FGF3, SLC37A1, and SLC1A1 have all been previously 
associated with breast cancer.22–28 SLC7A3, PRKCZ, JAG2, 
GABRR1, DDX3Y, and PCDHGA3 have been previously 
associated with other types of cancer.29–34 Our results, which 
agree with previously published results, indicate that methy-
lation patterns of the tumor itself may impact the methyla-
tion patterns present in peripheral blood. Development of a 
model that can accurately predict stage of cancer from DNA 
methylation or other genomic profiles from peripheral blood 
samples and demographic information may have important 
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figure 3. Boxplot of β-values for CpG site cg19149522 (ZDHHC4), for all 
subjects, by stage of cancer.
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figure 4. Boxplot of β-values for CpG site cgl6807687 (PCDH21), for all 
subjects, by stage of cancer.
Table 6. Cross-tabulation of the observed (rows) versus predicted 
(columns) class for the aIC and the fully converged models.
AIC I IIA IIB IIIA CONvERgED I IIA IIB IIIA
I 20 1 0 0 I 21 0 0 0
IIa 0 29 0 0 IIa 0 29 0 0
IIB 0 4 11 0 IIB 0 0 15 0
IIIa 0 0 6 2 IIIa 0 0 0 8
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healthcare implications. We hope that our work here will help 
future development of less invasive, less expensive methods for 
determining the stage of cancer.
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